our results seem promising. Nevertheless, late relapses can occur, and the role of this procedure vs conventional treatment in very high-risk patients should be assessed Although more than 50% of Hodgkin's disease patients are cured with conventional chemotherapy, many will in prospective randomized studies. Keywords: high-risk Hodgkin's disease; autologous stem relapse and eventually die from their disease. Many efforts have been made to identify poor prognostic faccell transplantation; early intensive therapy tors that could be useful in selecting high-risk patients in 1st CR who may benefit from high-dose chemo/radiotherapy. However, the role of early transUp to 80% of patients with advanced Hodgkin's disease plantation in 1st CR remains unclear. We have retro-(HD) obtain a CR with current conventional chemospectively analyzed the results obtained with this protherapy, 1 while 20% are refractory to the initial treatment, cedure in 22 hospitals belonging to the Spanish and 30 to 40% of the initial responders eventually relapse. GEL/TAMO cooperative group. Twenty-seven patients, Relapsed patients are curable by means of salvage therapy of whom 19 were males, underwent autologous transin only 20 to 40% of cases. Therefore, half of the patients plantation for Hodgkin's disease in 1st CR between Janwith advanced HD are not cured with standard chemouary 1987 and January 1996. Remission had been achitherapy. In this disease, autologous hematopoietic stem cell eved after one (n = 22) or two (n = 5) lines of treatment.
groups have reported short experiences with ASCT for HD Histologic subtypes, according to Lukes Rye criteria 12 were, nodular sclerosis in 14 patients, lymphocyte depletion patients in 1st CR [9] [10] [11] or very good PR (VGPR). 11 In all of these series, HD patients had poor risk factors and were in four patients and mixed cellularity in nine patients. At diagnosis, all but six patients had stage IV HD according autografted after front-line therapy that included ABVDlike chemotherapy regimens. Regimen-related toxicity was to the Ann Arbor classification. 13 Twelve of the 27 patients (44%) had bulky mediastinal disease at diagnosis, 18 (67%) usually low and disease-free survival (DFS) ranged from 75 to 85%. Despite these encouraging results, it is unclear extranodal lesions and nine (33%) had bone marrow involvement. Six patients had four of these high-risk facwhether a substantial proportion of this cohort of patients was already 'cured' before transplant. Up to now, the optitors, 12 had three adverse features and six patients had two factors. mal risk factors for the selection of candidates for autologous transplantation in first CR remain to be defined and the Ten patients had received conventional 28-day treatment as first-line therapy, 12 an alternating regimen early and late complications of this procedure in earlyphase patients merit further study.
(MOPP/ABVD-like), three had been treated with ABVD and the last two patients received a hybrid regimen. Four With this objective, we have retrospectively analyzed the results of ASCT in poor prognosis HD patients in 1st CR patients received adjuvant radiotherapy to reach or consolidate the 1st CR. Most achieved CR after first-line chemotreated at 22 Spanish institutions. All these patients were reported to the registry of the Spanish GEL/TAMO Cotherapy, but four patients only achieved a PR and one did not respond (18.5% of the whole series). Two of these operative Group for Bone Marrow Transplantation in Lymphomas.
patients received the COPP regimen as second-line treatment, two patients the mini-BEAM combination and one patient an alternating regimen (MOPP/ABVD). Median Materials and methods (range) time between 1st CR and autologous transplantation was 4.4 (0.9-14) months.
Patient characteristics at diagnosis
Three hundred and thirty-six consecutive patients with HD Hematopoietic stem cell procurement who underwent ASCT between January 1987 and January 1996 in 22 Spanish centres belonging to the GEL/TAMO Nine patients had BM harvested and cryopreserved without in vitro purging. BM was harvested after a median time Cooperative Group were eligible for this study, and 27 who were autografted in 1st CR (19 males and eight females, from CR of 2.5 (0.5-5) months. The median (range) time elapsed between marrow collection and autologous infusion with a median age of 30 (17-51) years) were selected for further analysis.
was 2 (1-7) months. Median numbers of mononucleated cells (MNC) and infused CFU-GM were 3.4 (2.1-Pretransplant characteristics are presented in Table 1 . The main transplant-related toxicity was hematological CY (1.5 g/m 2 i.v.) was used as mobilizing chemotherapy with a median (range) time to achieve an absolute neutroin 13 cases followed by G-CSF (six patients) at 5 g/kg/day phil count Ͼ0.5 × 10 9 /l of 14 (8-56) days and a platelet s.c. or GM-CSF (n = 8) (5 g/kg/day s.c.) and in two count Ͼ50 × 10 9 /l without platelet support of 16 (8-240) patients circulating progenitor cells were collected after the days. Hematological recovery was significantly faster in ESHAP regimen plus G-CSF. Median numbers of MNC, patients grafted with PBSC than from BM cells, both for CFU-GM and CD34 + cells were 6.7 (3.1-20) × 10 8 /kg, 10 neutrophils (median 11 (8-37) vs 22 (12-56) days, P Ͻ (8-40) × 10 4 /kg and 3.9 (2.1-18.1) × 10 6 /kg, respectively. 0.02) and platelets (median 14 (8-123) vs 35.5 (13-155) days, P Ͻ 0.02). All patients developed fever of unknown origin during the neutropenic period which resolved with High-dose therapy regimen broad-spectrum antibiotics. There was one episode of documented oropharingeal candidiasis and one case of Patients were nursed in single hospital rooms with laminar herpetic estomatitis. airflow or conventional reverse isolation procedures and Extrahematological toxicities were mild and consisted received prophylactic antibiotics and acyclovir if they were mainly of nausea, vomiting, mucositis and diarrhea. Of herpes simplex virus seropositive. All blood components note, there was no case of veno-occlusive disease, intergiven after transplant were irradiated to 15 Gy and were stitial pneumonitis or toxic death related to the procedure. given as needed to maintain a hemoglobin level Ͼ8 g/dl and a platelet count Ͼ20 × 10 9 /l. Empiric broad spectrum antibiotics, antifungal therapy and total parenteral nutrition Overall outcome and progression-free survival were given as indicated by the patient's general condition.
Currently, 25 patients are alive. Twenty-one of them (81%) All but three patients were conditioned with chemoare in continuous CR (CCR) 8-66 months (median, 30 therapy: 16 patients received the CBV regimen (CY 1.5 months) after transplant (Table 2) . Four patients relapsed g/m 2 /day for 4 days, etoposide 125 mg/m 2 /12 h for 3 days 8, 17.5, 22 and 26 months after autografting and are alive and BCNU (total doses ranging from 300 to 800 mg/m 2 in 2nd CR after salvage chemotherapy regimens at 27, 39, split over 1 to 3 days)), four patients received the BEAM 42 and 50 months after transplant, respectively. In two of combination (BCNU at doses ranging from 300 to 400 these patients, the second CR is longer than the time mg/m 2 for 1 day, etoposide 200 mg/m 2 /12 h for 4 days, elapsed from the transplant to the 1st relapse. One patient cytarabine 200 mg/m 2 /12 h for 4 days and melphalan 140 relapsed 92 months after transplant and died from disease mg/m 2 for 1 day) and four patients the BEAC regimen progression 5 months later. One patient died in CR from (BCNU 300 mg/m 2 for 1 day, etoposide 200 mg/m 2 /12 h a secondary malignancy 30 months after transplant. The for 4 days, cytarabine 200 mg/m 2 /12 h for 4 days and CY estimated DFS for the whole series is 72% at 7 years with 35 mg/kg for 4 days). In three cases, CY (60 mg/kg/day for a median follow-up of 30 months (Figure 1 ). Estimated OS 2 days) and fractionated TBI (1200-1300 cGy) were used.
is 93% at 7 years with a median follow-up of 30 months Hematopoietic progenitors were infused on day 0. The ( Figure 2 ). All survivors have a Karnofsky score of 100%. median interval between diagnosis and autologous transplant was 12 (6-24) months.
Discussion

Tumor evaluation
Over the past years, several groups have reported long term DFS of 25 to 45% after high-dose chemotherapy with HD was evaluated 3 months post-transplant, and thereafter every 6 to 12 months depending on the center and the ASCT in patients with relapsed HD. 4, [16] [17] [18] More recently, different groups have reported improvements in event-free patient's condition. Complete response was defined as the absence of all evaluable lesions on physical examination survival rates in patients with relapsed or persistent disease when ASCT is performed early in the course of their disand imaging studies, or as the absence of progression of residual lesions. 14 ease, at the first sign of progression 19, 20 (47% 5-year DFS 19 and 44% 5-year DFS 20 ). These improved results could be due to a reduction in the procedure-related mortality in less heavily pre-treated patients and to decreased intrinsic tumor Statistical analysis resistance. Nevertheless, since the cure rate in relapsed patients does not exceed 50% it seems reasonable to invesStudent's t-test for unpaired data from different samples was used to compare quantitative variables. The level of tigate the role of early high-dose therapy in patients at high risk of relapse in CR or VGPR with standard first-line significance in all cases was set at P Ͻ 0.05.
In DFS curves, censored observations reflected patients chemotherapy.
As a first step, reliable high-risk factors should be identalive and disease-free and failures, patients who relapsed or died in CR. Event-time curves were plotted using the ified to select optimal candidates for these early intensification programs. Two main prognostic factor models are method of Kaplan and Meier. ment. Strauss and coworkers 6 found that the five factors being used for this purpose. The Scotland and Newcastle Lymphoma group defined a numerical prognostic index 7 in most strongly associated with decreased survival in a multivariate analysis were age more than 45 years, high LDH, which age, clinical stage, absolute lymphocyte count, hemoglobin level and tumor burden are used. Patients with an low hematocrit, inguinal node involvement and a mediastinal mass greater than 0.45 the thoracic diameter. Patients index above 0.5 have a risk of death from progressive disease of 60 to 70% within 4 years from diagnosis. This index with none or only one of these adverse characteristics (aproximately 60% of the whole series) had a life expectis easily applicable to all patients at diagnosis and could allow appropriate selection for consolidation with ASCT. 21 ancy significantly longer (only 5% of them died) than the group of patients with two or more adverse characteristics With this model, not only stage IV but also stage II and III bulky disease would be selected for more intensive treatat diagnosis (40% of the series) in which 50% of the patients died within 62.4 months. Although these prognosfor these differences is that both our study and the EBMT report include patients transplanted over a long period of tic factors were prospectively validated in a larger group of patients, their final impact on patient survival is not unitime in different institutions. Relapse of the primary disease seems to be the main problem after transplantation for highversally accepted. For example, Phillips' analysis 22 of 65 patients with two or more bad prognostic factors as risk HD in first remission. Although in several series more than 75% of the relapses occurred during the first 12 described by Strauss found that the relapse-free survival was greater than 60% at 16 years. Similarly, the German months after ASCT, 9,20,21 this was not the case in ours. Three of five patients relapsed more than 2 years after transHodgkin's Lymphoma Study Group applied the two mentioned sets of prognostic factors to 561 stage III and IV plantation and one relapsed at 92 months, which is the latest relapse reported after a transplant in 1st CR. Surprisingly, patients and only found a 15% difference in DFS between good and bad prognostic groups. 23 four of the relapsed cases achieved a long-lasting second CR with conventional chemotherapy which translated into Carella et al 8 from Genoa were the first to publish on the role of ABMT for high-risk HD in 1st CR after the prolonged overall survival. Finally, when analysing high-dose therapy and ASCT in MOPP/ABVD regimen. This study included 15 HD patients in 1st CR with the following characteristics: stage IVB, 1st CR HD, the possibility of late complications should be considered. No data are available to predict the long-term LDH Ͼ 400, at least two extranodal sites, bulky mediastinum and Karnofsky performance status у80%. Thirteen effects on lung function and endocrine function in this group of patients. Second malignancies are well-known patients were alive and in CCR with a median follow-up of 36 months post-transplant, one relapsed and one died complications, which occurred in one of our cases. These and other factors should be analysed in future from transplant-related toxicity. These results have been recently updated:
10 22 patients were transplanted and 18 studies of ASCT in 1st CR HD. In the meantime, the low transplant-related mortality and promising DFS should remain alive in CCR at a median time of 66 (2-101) months after transplantation. Only one toxic death was observed encourage the inclusion of such patients in prospective randomized studies to compare this approach with convendue to interstitial pneumonitis, and two patients died from disease progression. These results compared favourably tional chemotherapy followed by ASCT in relapse. These studies should offer more definite conclusions on the real with a matched control group of patients in CR after conventional chemotherapy of whom only eight out of 24 impact of the early transplant in high-risk HD. CR, a circumstance that has also been considered an of refractory Hodgkin's disease by high-dose combination adverse prognostic factor for prolonged DFS. 25, 26 chemotherapy and autologous bone marrow transplantation.
Hematological recovery was complete in all patients and, 24 A possible explanation
